• San Antonio Breast Cancer Symposium 2016
Past Meetings
Alerts
Best of SABCS

Best of SABCS USA
January 21, 2017
Boston, MA

Breast cancer trial results are critically important worldwide. For oncologists unable to attend the US meeting, these officially licensed events offer the actual presentations and posters from the meeting in their home country. To inquire about sponsoring a program in your country contact: Lidia.martin@encoremeded.com

Future Dates
News
  1. Is everolimus active in aromatase inhibitor resistant breast cancer?
  2. Come listen to the latest phase III clinical trials on the extended use of aromatase inhibitors, DATA, NSABP B42 and BOOG 2006-05) and Dr…. discussing these pivotal clinical trials
  3. The latest results on the role of the immune system in all breast cancer subtypes will be presented at SABCS this year
  4. Randomized PARP inhibitor clinical trial, somatic BRCA1/2 mutations in breast cancer and other abstracts will be presented that will change the landscape of treating breast cancer
  5. The PERTAIN trial will be presented evaluating for the first time the role of trastuzumab, pertuzumab and an aromatase inhibitor combination in the metastatic setting. The NSABP B52 will evaluate the role of combination of antiHER2 and antiendocrine therapy in the neoadjuvant setting.
  6. Can PAM50 predict pathologic complete response? Find out the first results of the PAMELA clinical trial at SABCS this year
  7. How does radiotherapy impact the cosmetic outcomes of reconstruction? A prospective multicenter clinical trial will provide the answer
  8. A novel BRD4 inhibitor can circumvent endocrine resistance
  9. BELLE-3: the results of the first phase III randomized clinical trial with a PI3K inhibitor in metastatic breast cancer will be presented at SABCS.
  10. What is the impact of low fat diet and exercise on breast cancer outcomes? SABCS will have the answer.
  11. Can a bisphosphonate, ibandronate, improve outcomes in early stage breast cancer? The TEAM IIB trial will provide the answer.